HC Wainwright Brokers Reduce Earnings Estimates for Ardelyx

Posted by Brenda Bartman on Aug 12th, 2026

Ardelyx, Inc. (NASDAQ:ARDX – Free Report) – Investment analysts at HC Wainwright reduced their FY2027 earnings estimates for shares of Ardelyx in a note issued to investors on Friday, August 7th. HC Wainwright analyst M. Caufield now expects that the biopharmaceutical company will post earnings per share of $0.35 for the year, down from their previous forecast of $0.36. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Ardelyx’s FY2028 earnings at $0.66 EPS.

A number of other research firms have also weighed in on ARDX. TD Cowen dropped their price objective on Ardelyx from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Friday. LADENBURG THALM/SH SH started coverage on Ardelyx in a research note on Tuesday, June 16th. They set a “buy” rating and a $16.00 target price on the stock. Citigroup lowered their price target on Ardelyx from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Monday. BTIG Research dropped their price target on Ardelyx from $17.00 to $14.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Finally, Zacks Research lowered shares of Ardelyx from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Get Our Latest Research Report on ARDX

Ardelyx Price Performance

NASDAQ:ARDX opened at $3.94 on Monday. The business’s 50-day simple moving average is $5.31 and its two-hundred day simple moving average is $6.02. Ardelyx has a 52 week low of $3.90 and a 52 week high of $8.40. The stock has a market cap of $981.81 million, a PE ratio of -17.91 and a beta of 0.70. The company has a quick ratio of 3.28, a current ratio of 3.49 and a debt-to-equity ratio of 1.37.

Ardelyx (NASDAQ:ARDX – Get Free Report) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). Ardelyx had a negative return on equity of 35.57% and a negative net margin of 12.35%.The firm had revenue of $120.88 million during the quarter, compared to the consensus estimate of $121.03 million. During the same period in the prior year, the company posted ($0.08) EPS. The company’s quarterly revenue was up 34.3% on a year-over-year basis.

Insiders Place Their Bets

In other Ardelyx news, insider Mike Kelliher sold 7,248 shares of the stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $6.27, for a total transaction of $45,444.96. Following the completion of the transaction, the insider owned 357,418 shares in the company, valued at $2,241,010.86. This trade represents a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Eric Duane Foster sold 7,998 shares of Ardelyx stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $6.27, for a total transaction of $50,147.46. Following the completion of the transaction, the insider directly owned 417,972 shares of the company’s stock, valued at $2,620,684.44. The trade was a 1.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 24,572 shares of company stock valued at $154,066. 5.30% of the stock is currently owned by insiders.

Institutional Trading of Ardelyx

Several hedge funds have recently made changes to their positions in ARDX. Knott David M Jr bought a new stake in shares of Ardelyx in the 1st quarter valued at approximately $1,240,000. AIGH Capital Management LLC boosted its holdings in shares of Ardelyx by 479.3% in the 4th quarter. AIGH Capital Management LLC now owns 1,150,000 shares of the biopharmaceutical company’s stock worth $6,704,000 after purchasing an additional 951,500 shares during the period. Vanguard Group Inc. increased its position in shares of Ardelyx by 3.3% during the 4th quarter. Vanguard Group Inc. now owns 18,979,483 shares of the biopharmaceutical company’s stock valued at $110,650,000 after purchasing an additional 610,162 shares during the last quarter. Rubric Capital Management LP bought a new position in shares of Ardelyx during the 1st quarter valued at approximately $11,147,000. Finally, Tudor Investment Corp ET AL purchased a new stake in Ardelyx during the 3rd quarter valued at $688,000. 58.92% of the stock is currently owned by hedge funds and other institutional investors.

Ardelyx News Roundup

Here are the key news stories impacting Ardelyx this week:

Positive Sentiment: Analysts maintain bullish ratings and substantial upside targets. HC Wainwright reiterated its “Buy” rating and $13 price target, while Citigroup maintained a “Buy” rating despite reducing its target from $14 to $11. BTIG Research also set a $14 target. These targets imply significant potential upside if Ardelyx executes on its growth plans. Citigroup lowers Ardelyx price target BTIG Research cuts Ardelyx price target
Positive Sentiment: Long-term earnings expectations edged higher. HC Wainwright increased its FY2030 EPS forecast slightly to $1.61 from $1.60, suggesting the firm continues to see meaningful long-term profitability potential. HC Wainwright Ardelyx earnings forecast
Neutral Sentiment: HC Wainwright issued a FY2027 earnings forecast. The available report does not provide the specific estimate, limiting its immediate significance for investors. FY2027 earnings forecast for Ardelyx
Negative Sentiment: Near-term earnings estimates were materially reduced. HC Wainwright lowered its Q3 2026 forecast from $0.05 to a loss of $0.06 per share, cut its Q4 forecast from $0.10 to $0.01, and reduced FY2026 expectations from a $0.03 loss to a $0.26 loss. The revisions point to weaker near-term profitability and are the clearest negative catalyst.
Neutral Sentiment: Short-interest data showed no meaningful position. The report lists short interest at zero shares both periods, with a zero-day days-to-cover ratio. Because the figures produce an undefined percentage change, they provide no reliable signal about short-selling pressure.

Ardelyx Company Profile

(Get Free Report)

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.